CXD101 is a Selective and Orally Active Class I HDAC Inhibitor
Aberrant expression of classical HDACs associates with a variety of malignancies, including solid and hematological tumors. HDACs have also been found broadly dysregulated in multiple myeloma (MM). In particular, the…